One of these stocks may look cheaper at first glance, but the faster-growing company already has more momentum in the parts ...

Investors tracking Biogen stock were expecting the company to post only a slight year-over-year gain in headline net income, ...

For now, oil prices, the status of the Strait of Hormuz, and the duration and outcome of the war are likely to be the main ...

Kosmos Energy hit a 52-week high as shares pushed past analyst targets, even as skepticism lingers over whether offshore ...

Macroeconomic fears aside, Amazon has laid a solid foundation for growth that will serve the company -- and investors -- well ...

You can work as much as you want when collecting Social Security -- but if you earn too much, you could end up temporarily ...

That said, the situation isn't all peaches and cream. Carnival is still a long way away from paying off its pandemic-era debt ...

It sent the company a warning letter about a TV ad and a podcast episode about Anktiva. ImmunityBio sounded a contrite note in response. That regulator is the U.S. Food and Drug Administration (FDA).

JPMorgan Chase CEO just raised an alarm about the destructive impact rising inflation could have on stock prices.

Tesla fell after a delivery miss led to analyst cuts, with rising inventory weighing on sentiment despite strong sales in key ...

Energy Transfer pays an attractive forward yield of 7%, and it's raised its distributions annually for the past five ...

Neurocrine’s rare-disease push, anchored by Soleno’s VYKAT XR, reshapes biotech dealmaking focus, today, April 6, 2026.